Compare HRMY & HTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRMY | HTO |
|---|---|---|
| Founded | 2017 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2020 | 1994 |
| Metric | HRMY | HTO |
|---|---|---|
| Price | $42.11 | $64.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $44.11 | ★ $62.00 |
| AVG Volume (30 Days) | ★ 603.1K | 286.1K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.05% |
| EPS Growth | ★ 7.97 | 1.74 |
| EPS | ★ 1.84 | 0.49 |
| Revenue | ★ $868,453,000.00 | $800,590,000.00 |
| Revenue This Year | $19.75 | $10.26 |
| Revenue Next Year | $12.88 | $7.06 |
| P/E Ratio | ★ $23.20 | $132.47 |
| Revenue Growth | ★ 21.51 | 6.97 |
| 52 Week Low | $25.52 | $43.75 |
| 52 Week High | $43.49 | $67.09 |
| Indicator | HRMY | HTO |
|---|---|---|
| Relative Strength Index (RSI) | 69.47 | 60.58 |
| Support Level | $34.87 | $55.58 |
| Resistance Level | N/A | $66.57 |
| Average True Range (ATR) | 1.24 | 1.15 |
| MACD | 0.29 | 0.02 |
| Stochastic Oscillator | 86.77 | 97.72 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.